Skip to main content
. 2024 Jun 3;25(1):90. doi: 10.1186/s10194-024-01790-7

Fig. 2.

Fig. 2

Results for the no switch subgroup. Mean monthly migraine days (MMD) during the first 6 months of treatment (A), percentage of patients achieving ≥ 50% reduction in MMD at 3 and 6 months (B), average HIT-6 (C) and MIDAS (D) scores at baseline, 3 and 6 months for the no switch subgroup. Error bars represent 95% confidence intervals